Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lonoctocog Alfa→

Lonoctocog Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1357447-52-9
Molecular formula
C7474H11438N2024O2184S78
Molecular weight
~170000 g/mol
Drug class
Recombinant single-chain coagulation factor VIIIantihaemorrhagic biologic
Mechanism of action
Replaces deficient factor VIII in the intrinsic coagulation pathway. Activated factor VIII functions as a cofactor for activated factor IX, accelerating factor X activation and supporting thrombin generation and fibrin clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management, under the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/afstyla · https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/afstyla

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lonoctocog Alfa Environmental Risk Assessment (ERA) (the Lonoctocog Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.